Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | Phase II trial show nilotinib achieves remission Philadelphia-positive acute lymphocytic leukaemia

Oliver Ottmann • 5 Dec 2014
ASH 2014
Acute Lymphoblastic Leukemia Nilotinib

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Oliver Ottmann (Goethe-University Hospital, Frankfurt, Germany) discusses a Trial of the European Working Group for Adult ALL (EWALL-PH-02), which evaluated nilotinib and chemotherapy for first-line treatment in elderly patients with de novo Philadelphia chromosome/BCR-ABL1-positive acute lymphoblastic leukaemia.

More from Oliver Ottmann

Impact of increased drug availability on acute leukemia
3:38
Impact of increased drug availability on acute leukemia
Oliver Ottmann • 3 Jul 2020
Molecular profiling to determine treatment for ALL and AML
3:24
Molecular profiling to determine treatment for ALL and AML
Oliver Ottmann • 3 Jul 2020
How age as a prognostic factor affects treatment options for ALL
3:07
How age as a prognostic factor affects treatment options for ALL
Oliver Ottmann • 3 Jun 2020
Treatment options for Ph+ ALL
5:23
Treatment options for Ph+ ALL
Oliver Ottmann • 3 Jul 2020

Related Videos

Advances in precision-engineered T-cell immunotherapy for alloSCT in AML, ALL and MDS
10:54
Advances in precision-engineered T-cell immunotherapy for alloSCT in AML, ALL and MDS
Samer Srour • 19 Sep 2026
New horizons in Ph+ ALL: the evolving role of bispecific antibodies
1:20
New horizons in Ph+ ALL: the evolving role of bispecific antibodies
Josep-Maria Ribera • 14 Sep 2026
NGS-MRD assessment and targeted treatment selection in ALL
1:48
NGS-MRD assessment and targeted treatment selection in ALL
Josep-Maria Ribera • 14 Sep 2026
Avoiding common pitfalls when managing patients with ALL outside of specialist centers
3:52
Avoiding common pitfalls when managing patients with ALL outside of specialist centers
Bijal Shah • 10 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals